Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
1(16.7%)
Early Phase 1
1(16.7%)
6Total
Phase 1(4)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07474727Phase 2Not Yet Recruiting

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

Role: lead

NCT06209580Phase 1Recruiting

AMT-253 in Patients With Advanced Solid Tumours

Role: lead

NCT05725291Phase 1Recruiting

AMT-116 in Patients With Advanced Solid Tumors

Role: lead

NCT06400485Early Phase 1Recruiting

AMT-676 in Patients With Advanced Solid Tumors

Role: lead

NCT06782334Phase 1Recruiting

AMT-116 in Patients with Solid Tumors

Role: lead

NCT05498597Phase 1Unknown

AMT-151 in Patients With Selected Advanced Solid Tumours

Role: lead

All 6 trials loaded